Status:
COMPLETED
Haptoglobin Phenotype and Cardiovascular Complications in Diabetic Patients
Lead Sponsor:
Dr. Shany Blum
Collaborating Sponsors:
Clalit Health Services
Conditions:
Diabetes
Cardiovascular Disease
Eligibility:
All Genders
55+ years
Brief Summary
3054 diabetic patients were screened for Haptoglobin Phenotype as part of the ICARE study (NCT00220831) and composite the I CARE Registry, 1434 Hp 2-2 patients were treated as part of the I CARE study...
Detailed Description
3054 diabetic patients from Clalit Medical Services were screened for Haptoglobin Phenotype as part of the ICARE study (NCT00220831) and composite the I CARE registry, 1434 Hp 2-2 patients were treate...
Eligibility Criteria
Inclusion
- These are the same patients as in I CARE registry so the criteria are the same as was for I CARE study Recruitment phase.
- Diabetic patients aged 55 and above
Exclusion
- Patient who takes antioxidant treatment will be asked to stop, or can't be included in the study
- Patients who had a CVD incident (MI, Stroke, TIA), Unstable angina pectoris, Uncontrolled HTN, will have to wait a month after stabilization to be included in the study
- Allergy to Vitamin E
Key Trial Info
Start Date :
April 1 2005
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
June 1 2008
Estimated Enrollment :
3054 Patients enrolled
Trial Details
Trial ID
NCT00448487
Start Date
April 1 2005
End Date
June 1 2008
Last Update
June 12 2015
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Clalit Health Services, Haifa and Western Galilee District
Haifa, Israel